Professional Documents
Culture Documents
Labelling changes
The Therapeutic Goods
Administration has announced
that it will update the Australian
approved names of ingredients
used in medicines to better align
with international standards,
as part of its international
harmonisation plans.
There will be a four year transition
period for the changes which is
expected to commence in Apr 2016.
While some changes are minor
- such as changing a y to an
i which wont affect how the
ingredient name is pronounced,
others are more significant and in
these cases medicine labels will
be required to use both the old
and new ingredient names for an
additional three years after the end
of the transition period.
The full list of name changes can
be viewed at www.tga.gov.au.
MEANWHILE the TGA has also
issued a warning about some
home based beauty salons which
may be using imported Botox which
has not been approved for supply
within Australia.
healthnotes.com.au
PHARMACYDAILY.COM.AU
GET
remuneration of pharmacies,
while Professor King recently stated
in an Australian Financial Review
article that the Location Rules are
anti-competitive and should be
removed.
The Guild trusts that the
panellists are not coming to this
Review with pre-determined
positions, and that all issues will
be considered on their merits, the
Guild said.
The Review was agreed to during
the Sixth Agreement negotiations
as a means of informing pharmacy
remuneration for the next
agreement and addressing any
anomalies around the Location
Rules which are in place until 2020.
Ley said the review will
undertake a transparent and
public assessment of the costeffectiveness of all parts of
remuneration, both to pharmacy
and wholesalers, as well as the
appropriateness of location rules,
reporting to the government in the
first half of 2017.
BIG
RESULTS
IN 2016
GUARANTEED
Todays issue of PD
Optimise dispensary
profitability
Boost front-of-shop
performance
Be the destination
for health in your
community
The latest in POS,
dispense, office
systems
Exceptional support
from a local operations
team and specialists at
our Member Support
Office
Plus, much more
w www.pharmacydaily.com.au
page 1
PHARMACYDAILY.COM.AU
sukin
FeverMates
TM
Myeloma approval
The US FDA has granted approval
to Ninlaro (ixazomib), made by
Takeda, which is the first and
only oral proteasome inhibitor
indicated in combination with
lenalidomide and dexamethasone
for the treatment of patients with
multiple myeloma.
Ninlaro is administered as a onceweekly tablet, with the coming just
months after Takeda submitted its
new drug application to the FDA in
Jul and subsequently being granted
Priority review status reflecting
the profound and continuing unmet
need for new treatments.
PHARMACIST POSITION
The Victorian Pharmacy Authority (VPA)
is responsible for the administration of
the Pharmacy Regulation Act 2010 and
wishes to appoint a part-time pharmacist
three days per week.
w www.pharmacydaily.com.au
page 2
EXPANDING NATIONALLY
For more information or to book a confidential meeting
contact Feras Karem on 0414 653 803
or feras@pharmacy4less.com.au
JOIN
NOW
PHARMACYDAILY.COM.AU
Health, Beauty
and New Products
DISPENSARY
CORNER
For product information, pricing, deals and orders, contact Strategic National Group in the following states
WA
NSW
VIC
SA/NT
QLD
TAS